Last updated 2026-07-27
TL;DR
Sirolimus (rapamycin) is FDA-labeled contraindicated for hypersensitivity to the drug and, combined with cyclosporine long-term, poses added risk in liver/kidney transplant. Off-label longevity users must weigh immunosuppression, mouth ulcers, lipid and glucose effects, wound-healing delays, and pregnancy risk against a lifespan benefit that so far exists only in mice, not confirmed human trials.
What is sirolimus actually contraindicated for, according to the FDA label?
The FDA label for Rapamune (sirolimus) lists formal contraindications for patients with "hypersensitivity to the active substance or to any of the excipients" [1]. That's the core legal contraindication. Beyond that, the label carries a boxed warning specific to liver transplant patients: sirolimus is not recommended in liver transplant recipients because of reports of increased risk of hepatic artery thrombosis, some leading to graft loss or death, and a boxed warning about excess mortality and graft loss when sirolimus is used with cyclosporine in kidney transplant patients more than 12 months post-transplant [1]. Sirolimus and rapamycin are the same molecule. Rapamycin was the original name (isolated from Streptomyces hygroscopicus, a soil bacterium found on Easter Island, or Rapa Nui, which is where the name comes from) and sirolimus is the generic drug name used on prescribing labels [1][2]. Fyarro (sirolimus protein-bound particles) and Hyftor (topical sirolimus) are newer FDA approvals for specific rare conditions, malignant PEComa and facial angiofibromas in tuberous sclerosis, respectively [3][4]. None of these approvals cover aging or lifespan extension. That use is entirely off-label, prescribed by physicians using their clinical judgment, and it's the whole reason this contraindications question matters so much: there's no FDA-reviewed label section written for healthy people taking low, intermittent doses for longevity. This matters for how you read the rest of this article. Everything below about immunosuppression, infection risk, and metabolic effects comes from data generated in sick transplant patients on daily, higher-dose sirolimus, or from mouse studies. Extrapolating that safety profile to a 45-year-old healthy adult taking 5-6mg once a week is a reasonable clinical bet many prescribers are making, but it is a bet, not a validated protocol backed by outcome trials in humans.
Who should absolutely not take sirolimus?
A few categories are close to absolute no-go zones, either by label language or by basic pharmacologic logic. Pregnancy and breastfeeding. Animal reproduction studies showed embryo-fetal toxicity, and the drug is not recommended during pregnancy; women of reproductive potential are advised to use effective contraception before, during, and for 12 weeks after stopping sirolimus therapy per the FDA label [1]. There is no scenario where longevity dosing during pregnancy makes sense. Active or serious infection. Sirolimus is an mTOR inhibitor developed specifically because it suppresses immune function. That's the mechanism that (probably) prevents organ rejection in transplant patients and it's the same mechanism that raises infection risk in everyone else. The label documents increased susceptibility to infection, including opportunistic infections, as a common adverse effect across sirolimus-treated populations [1]. Anyone with an active infection, a chronic unresolved infection (like untreated hepatitis or tuberculosis), or a history of recurrent serious infections needs a real conversation with a prescriber before starting, not a self-directed trial. Known hypersensitivity to sirolimus, its derivatives, or components of the formulation. This is the literal, on-label contraindication [1]. Uncontrolled hyperlipidemia. Sirolimus reliably raises triglycerides and LDL cholesterol; the label lists hyperlipidemia/hypertriglyceridemia among the most common adverse reactions, sometimes requiring lipid-lowering treatment [1]. Someone who already has severe, uncontrolled dyslipidemia is stacking a drug-induced problem on top of an existing one. Recent or planned major surgery. Sirolimus impairs wound healing. The label specifically warns about impaired or delayed wound healing, including risks like fascial dehiscence, incisional hernia, and anastomotic disruption, and recommends withholding sirolimus in the immediate peri-surgical period [1]. If you have a surgery scheduled, that's a hard stop, temporarily, on dosing.
What conditions call for extra caution rather than an outright ban?
Below the absolute contraindications sits a longer list of relative cautions, situations where a prescriber might still consider sirolimus but only with closer monitoring, dose adjustment, or a frank discussion of trade-offs. Liver impairment. Sirolimus is metabolized substantially by the liver (via CYP3A4) and impaired hepatic function slows clearance, raising blood levels. The label recommends reduced maintenance doses in patients with hepatic impairment and closer therapeutic drug monitoring [1]. Kidney disease. While sirolimus itself isn't classically nephrotoxic in the way calcineurin inhibitors like cyclosporine or tacrolimus are, proteinuria has been reported, and combining sirolimus with a calcineurin inhibitor can worsen kidney function. Anyone with existing chronic kidney disease needs baseline and follow-up renal function monitoring [1]. Diabetes or prediabetes. mTOR inhibition affects insulin signaling, and new-onset hyperglycemia and impaired glucose tolerance are documented adverse effects [1]. This doesn't mean diabetics can never use sirolimus, but it means glucose needs to be tracked, not assumed stable. Lung disease, especially interstitial lung disease. Rare but serious cases of interstitial pneumonitis have been reported with sirolimus, some occurring in patients with no other identifiable cause [1]. Anyone with pre-existing lung disease, or who develops unexplained shortness of breath or a new cough while on sirolimus, needs prompt evaluation, not a wait-and-see approach. History of poor wound healing or planned dental surgery. Related to the surgical caution above, but worth calling out separately because dental extractions and oral surgery are common and people forget sirolimus counts here too. Recent vaccination, especially live vaccines. Immunosuppressed patients are generally advised to avoid live vaccines, and vaccine response overall may be blunted on an mTOR inhibitor. This is standard immunosuppression logic, not sirolimus-specific labeling, but it applies.
Does sirolimus interact dangerously with other drugs?
Yes, and the interactions are a bigger practical problem for most longevity users than the standalone contraindications, because they're easy to miss if you're not looking. Sirolimus is metabolized by CYP3A4 and is a substrate for P-glycoprotein, so anything that strongly inhibits or induces those pathways changes blood levels substantially. Strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin, ritonavir) can spike sirolimus blood levels dramatically, and the label explicitly warns against coadministration of strong CYP3A4 inhibitors or advises significant dose reduction with careful monitoring [1]. Grapefruit and grapefruit juice inhibit intestinal CYP3A4 and are a well-known interaction risk with sirolimus, similar to the warning given for many statins and calcineurin inhibitors [1]. Strong CYP3A4 inducers (rifampin, St. John's Wort, carbamazepine) can drop sirolimus levels enough to risk therapeutic failure, whatever "therapeutic" means in an off-label longevity context where there's no validated target level anyway. Cyclosporine deserves its own mention because the interaction is central to the boxed warning: concurrent use with cyclosporine, especially past the first 12 months post-transplant, is linked to worse kidney function, higher lipids, and increased mortality/graft loss in the FDA-reviewed data [1]. Longevity users are unlikely to be on cyclosporine, but anyone on any immunosuppressant for an autoimmune condition needs a pharmacist or physician checking for this specifically before adding sirolimus.
What are the real risks people ask about most: immunosuppression, mouth ulcers, and metabolic effects?
These three come up constantly in off-label longevity discussions because they're the side effects people actually notice, versus abstract lab values. Immunosuppression is not a side effect, it's the mechanism. Sirolimus was developed and remains FDA-approved specifically because it suppresses T-cell activation and proliferation, which is why it prevents transplant rejection [1]. At transplant doses (daily dosing, therapeutic trough levels of roughly 4-20 ng/mL depending on regimen and combination therapy), this immunosuppression is substantial and sustained [1]. The theory behind intermittent, low-dose longevity protocols, popularized largely from work by Dr. Mikhail Blagosklonny and studied in some human pharmacokinetic and safety work by researchers including Dr. Joan Mannick's team, is that once-weekly dosing may preserve more of the beneficial mTOR inhibition (autophagy, reduced senescent cell burden) while limiting the chronic immune suppression seen with daily dosing. That's a real and reasonable hypothesis. It is not the same as proof it's safe long-term in healthy people, because no large trial has run the comparison over years. Mouth ulcers (stomatitis) are one of the most consistently reported adverse effects in sirolimus clinical trials, showing up in a meaningful share of transplant patients on the drug [1]. Anecdotally, longevity users on intermittent low-dose regimens report the same thing, often dose-dependent and improving with dose reduction or timing changes, but there's no formal dose-response study in this population to quote a real percentage from. Metabolic effects: elevated triglycerides, elevated LDL cholesterol, and new or worsened hyperglycemia are all documented adverse reactions in the FDA label and remain the most common lab abnormalities seen in sirolimus-treated patients [1]. This is exactly why baseline and periodic lipid panels and fasting glucose or HbA1c checks matter for anyone using sirolimus off-label; see Sirolimus Rx and blood work for what a reasonable monitoring schedule looks like. None of this is disqualifying on its own. It's a cost side of a cost-benefit equation where the benefit side, in humans, is still mostly theoretical.
What does the human evidence actually say about lifespan benefit, and how does that change the risk calculus?
This is the section that has to be honest: there is no completed human lifespan trial for sirolimus. None. Zero. Every headline you've seen about rapamycin adding years to life comes from animal studies, overwhelmingly mice. The anchor dataset is the National Institute on Aging's Interventions Testing Program (ITP), which tests candidate longevity compounds across three genetically diverse mouse cohorts at three sites (Jackson Laboratory, University of Michigan, University of Texas Health Science Center at San Antonio) to control for genetic and site-specific noise. Rapamycin has been the ITP's most consistently positive finding: in the original 2009 report, rapamycin fed starting at approximately 600 days of age (roughly 20 months, late in the mouse lifespan) extended median lifespan, with the effect stronger in females [5]. Harrison et al., writing in Nature, reported that "rapamycin extended median and maximal lifespan of both male and female mice, when fed beginning at 600 days of age" [5]. Later ITP publications with earlier start ages and different doses have reported male lifespan gains in roughly the 10-14% range and larger female gains, though exact figures vary by cohort, dose, and start age. That is genuinely the strongest, most replicated lifespan-extension signal of any compound the ITP has tested. Human data is a different story. The closest thing to a human trial is a study led by Joan Mannick and colleagues (funded by Novartis, published in Science Translational Medicine, 2014) testing an mTOR inhibitor (RAD001, an analog of rapamycin) in elderly volunteers. The study's own conclusion states that RAD001 treatment "improved the immune response to influenza vaccination in elderly subjects," a biomarker of immune function, not a lifespan or mortality outcome . No completed trial, to date, has measured whether rapamycin extends human lifespan or healthspan using the gold-standard endpoints (all-cause mortality, disability-free survival) that would let anyone say with confidence "this works in people." So the honest calculus is: real, replicated, strong evidence in mice; a documented and predictable side-effect profile in humans, but only from sick transplant patients on different dosing; and a genuine but unproven hypothesis that low-dose intermittent dosing shifts that risk-benefit ratio favorably for healthy adults. Nobody, including experienced prescribers, can currently tell you with certainty what the actual mortality-benefit-versus-mortality-risk trade-off looks like in a 50-year-old healthy adult, because that trial hasn't been run. For a fuller breakdown of what the research does and doesn't show, see Sirolimus Rx results: what the research shows and Sirolimus Rx before and after claims.
How does the contraindication picture differ between transplant dosing and off-label longevity dosing?
| Dosing frequency | Daily, continuous | Typically weekly or every-other-week, intermittent | |
|---|---|---|---|
| Typical goal trough level | Often 4-20 ng/mL depending on regimen and combination therapy [1] | No FDA-validated target; protocols vary by prescriber | |
| Patient population | Organ transplant recipients, already immunosuppressed by necessity | Generally healthy adults choosing suppression electively | |
| Evidence base for the specific use | FDA-reviewed trials supporting transplant rejection prevention [1] | Mouse lifespan data (ITP) [5]; no completed human lifespan trial | |
| Monitoring standard | Established, protocolized trough-level and lab monitoring | Ad hoc, varies widely by prescriber, no official standard | |
| Boxed warnings apply | Yes, directly (hepatic artery thrombosis in liver transplant; cyclosporine combination risk in kidney transplant) [1] | Warnings inform risk awareness but population and dosing differ substantially | The practical upshot: the contraindications on the label were written for and studied in daily-dosed transplant patients. Intermittent low-dose regimens plausibly reduce some risks (chronic immunosuppression, metabolic derangement) relative to daily dosing, based on pharmacokinetic reasoning and some human biomarker studies , but that plausibility has not been confirmed by a dedicated safety trial in the specific population using it for longevity. If you're trying to figure out where your body falls on this spectrum, dose matters enormously; see the Sirolimus Rx dosage calculator for how prescribers typically size intermittent regimens by weight and goal. |
This distinction gets lost constantly, so it's worth laying out side by side. | Factor | Transplant (FDA-approved use) | Off-label longevity use |
What lab work and monitoring should happen before and during treatment?
Given the metabolic and immune risks above, baseline labs before starting and periodic recheck labs during treatment are the minimum reasonable safety net, even though there's no FDA-mandated monitoring schedule for off-label longevity use specifically. A sensible baseline panel, drawn from what transplant monitoring protocols and prescriber practice suggest, generally includes a complete blood count (to catch the anemia, leukopenia, and thrombocytopenia sirolimus can cause) [1], a fasting lipid panel (triglycerides and LDL are the ones that move) [1], fasting glucose or HbA1c [1], and a basic metabolic panel including kidney function markers. Some prescribers also check a baseline sirolimus trough level a few weeks into a stable regimen, since individual clearance varies a lot person to person. Ongoing monitoring, particularly around dose changes or new drug interactions, should recheck the same panel. Anyone who develops unexplained shortness of breath, a persistent cough, unusual swelling, or new mouth sores that don't resolve needs to flag it to their prescriber rather than push through. For the fuller monitoring cadence and what specific values to watch, see Sirolimus Rx and blood work and Sirolimus Rx long term side effects, which covers what happens with years, not weeks, of exposure.
How should someone actually decide whether to start, given these contraindications?
Start with the hard stops. If you're pregnant, trying to conceive, have an active infection, have known hypersensitivity to sirolimus, or have surgery scheduled in the near future, this isn't the time, full stop. Then work through the relative cautions honestly: existing liver or kidney disease, diabetes, lung disease, uncontrolled lipids, and a full medication list checked against CYP3A4 interactions. This is not a supplement where you can eyeball a decision. Sirolimus is a prescription drug with a real, FDA-documented adverse effect profile, and the honest off-label use case rests on a real but unproven extrapolation from very strong mouse data to unproven human benefit. That's exactly why the route that makes sense is a provider-reviewed one: bloodwork before starting, a prescriber who actually looks at your history against the contraindications above, and dosing based on your labs and goals rather than a forum post. Sirolimus Rx connects patients with that kind of provider review and works with a licensed pharmacy partner for fulfillment; it does not compound or manufacture the drug itself. Whatever route you use, the bar should be the same: real labs, a real prescriber conversation about your specific contraindication risk, and a monitoring plan, not a guess.
Frequently asked questions
Is sirolimus the same thing as rapamycin?
Yes. Rapamycin is the original name for the compound, isolated from a bacterium found on Easter Island (Rapa Nui). Sirolimus is the generic drug name used on FDA prescribing labels like Rapamune. They are the same molecule; the names are used interchangeably in research and in prescriptions.
Can you take sirolimus while pregnant or breastfeeding?
No. The FDA label advises against use in pregnancy due to embryo-fetal toxicity shown in animal studies, and recommends effective contraception before, during, and for 12 weeks after stopping sirolimus. There's no accepted safety data supporting use during breastfeeding either, so most prescribers treat this as an absolute contraindication.
Does sirolimus interact with grapefruit?
Yes. Grapefruit and grapefruit juice inhibit intestinal CYP3A4, the enzyme that metabolizes sirolimus, which can raise blood levels of the drug. The FDA label flags this interaction directly. Most prescribers advise avoiding grapefruit products consistently while on sirolimus rather than trying to time around doses.
Is sirolimus safe for someone with diabetes?
Not automatically contraindicated, but it needs caution. Sirolimus can cause new-onset hyperglycemia and impaired glucose tolerance even in people without prior diabetes, per the FDA label. Anyone with existing diabetes or prediabetes should have fasting glucose or HbA1c checked at baseline and monitored regularly while on the drug.
Why does sirolimus cause mouth ulcers?
Stomatitis (mouth ulcers) is one of the most commonly reported adverse effects in sirolimus clinical trials, though the exact mechanism isn't fully settled; it's thought to relate to mTOR inhibition's effect on rapidly dividing oral mucosal cells. It's often dose-related and may improve with a lower dose or adjusted timing, but persistent ulcers should be reported to a prescriber.
Has any human study proven sirolimus extends lifespan?
No. No completed human trial has measured whether sirolimus extends lifespan or healthspan using mortality or disability-free survival endpoints. The strong lifespan-extension evidence comes from the NIA's Interventions Testing Program in mice, where rapamycin extended median and maximal lifespan in both sexes, not from human trials.
Can you take sirolimus with other immunosuppressants or autoimmune drugs?
This needs direct prescriber and pharmacist review. Combining sirolimus with cyclosporine, especially beyond 12 months post-transplant, carries an FDA boxed warning for increased mortality and graft loss risk in kidney transplant patients. Anyone on any immune-modulating drug for an autoimmune condition should not add sirolimus without that interaction specifically checked.
Does sirolimus affect wound healing or surgery recovery?
Yes. The FDA label warns that sirolimus can impair or delay wound healing, including risks like fascial dehiscence and anastomotic disruption, and recommends withholding it around the time of surgery. Anyone with planned surgery, including dental surgery, should discuss timing of sirolimus discontinuation with their prescriber beforehand.
What labs should be checked before starting sirolimus for longevity use?
A reasonable baseline includes a complete blood count, fasting lipid panel, fasting glucose or HbA1c, and kidney function markers, given sirolimus's documented effects on blood counts, lipids, and glucose. There's no FDA-mandated monitoring schedule for off-label use specifically, so this baseline-then-recheck approach is a prescriber judgment call, not a regulated protocol.
Is low-dose intermittent rapamycin safer than daily transplant dosing?
It's plausible but not proven. Intermittent, once-weekly-style dosing is theorized to reduce chronic immunosuppression and metabolic side effects compared to the daily dosing used in transplant patients, based on pharmacokinetic reasoning and small human biomarker studies. No dedicated long-term safety trial has confirmed this in the specific population using it for longevity.
Who should never take sirolimus under any circumstances?
Anyone with known hypersensitivity to sirolimus or its derivatives, anyone pregnant or trying to conceive, and anyone with an active serious infection are the clearest hard-stop cases based on FDA label contraindications and warnings. Liver transplant patients are also specifically warned against sirolimus use due to hepatic artery thrombosis risk.
Can sirolimus cause lung problems?
Rare but serious cases of interstitial pneumonitis (lung inflammation) have been reported with sirolimus, sometimes with no other identifiable cause, according to the FDA label. Anyone with pre-existing lung disease should flag this before starting, and anyone who develops new unexplained cough or shortness of breath while on the drug should get evaluated promptly.
Sources
- NIH National Library of Medicine, PubChem sirolimus compound summary: Sirolimus (rapamycin) was isolated from Streptomyces hygroscopicus found on Easter Island (Rapa Nui)
- FDA, Hyftor (sirolimus topical gel) approval, NDA 213478: Hyftor (topical sirolimus) is FDA-approved for facial angiofibroma associated with tuberous sclerosis complex
- Harrison DE, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460(7253):392-395.: Rapamycin extended median and maximal lifespan in genetically heterogeneous mice across NIA ITP cohorts when started at approximately 600 days of age
- Mannick JB, et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine. 2014;6(268):268ra179.: An mTOR inhibitor (RAD001) improved influenza vaccine response in elderly volunteers, a human immune biomarker study, not a lifespan trial
- ClinicalTrials.gov, PEARL Trial record: An ongoing study evaluating low-dose intermittent rapamycin in healthy older adults has not yet published peer-reviewed hard outcome data